tiprankstipranks
Trending News
More News >
M1 Kliniken AG (DE:M12)
XETRA:M12
Germany Market
Advertisement

M1 Kliniken AG (M12) AI Stock Analysis

Compare
12 Followers

Top Page

DE:M12

M1 Kliniken AG

(XETRA:M12)

Select Model
Select Model
Select Model
Outperform 73 (OpenAI - 4o)
Rating:73Outperform
Price Target:
€18.00
▲(12.50% Upside)
M1 Kliniken AG's strong financial performance is the primary driver of its stock score, supported by positive technical indicators. The valuation is reasonable, providing a balanced investment case. The absence of earnings call data and corporate events does not impact the score.

M1 Kliniken AG (M12) vs. iShares MSCI Germany ETF (EWG)

M1 Kliniken AG Business Overview & Revenue Model

Company DescriptionM1 Kliniken AG, together with its subsidiaries, operates medical centers for aesthetic and plastic surgery in Germany, Austria, the Netherlands, Switzerland, the United Kingdom, Croatia, and Australia. The company operates in two segments, Beauty and Trade. It develops and markets pharmaceutical, medical, and medical technology products for aesthetic medicine and cosmetic dermatology, as well as trades in pharmaceutical, biosimilars, and other medical products and devices in the areas of oncology, HIV, rheumatism, neurology, cardiovascular diseases, and narcotics. The company also engages in the acquisition, management, and sale of real estate, primarily in the health care sector. It offers its products to doctors, pharmacies, and wholesalers under the M1 Select brand. The company operates a network of outpatient specialist centers; and a specialized surgical clinic center, as well as 46 specialist centers under the M1 Med Beauty brand. M1 Kliniken AG was founded in 2007 and is based in Berlin, Germany. M1 Kliniken AG operates as a subsidiary of MPH Health Care AG.
How the Company Makes MoneyM1 Kliniken AG generates revenue through its network of clinics that offer aesthetic medical treatments and procedures. The company's key revenue streams include the fees charged for cosmetic procedures such as Botox, dermal fillers, and plastic surgeries. Additionally, M1 Kliniken AG may earn money from the sale of related beauty products and partnerships with pharmaceutical and cosmetic companies. The company focuses on maintaining competitive pricing while ensuring high standards of medical care, which helps attract a broad customer base, contributing to its earnings.

M1 Kliniken AG Financial Statement Overview

Summary
M1 Kliniken AG shows strong financial performance with robust revenue growth, improved profit margins, and significant cash flow improvements. The low leverage and solid equity position enhance financial stability, although a decrease in total assets and stockholders' equity requires monitoring.
Income Statement
80
Positive
M1 Kliniken AG has demonstrated robust growth in its revenue over the past years, with the 2024 figures showing a 7.23% increase from 2023. The gross profit margin improved to 18.75%, indicating better cost management. The net profit margin also increased to 4.72%. Notably, the EBIT and EBITDA margins improved, reflecting enhanced operational efficiency. These factors contribute to a strong income statement performance.
Balance Sheet
75
Positive
The company's balance sheet reflects a solid equity base with a favorable equity ratio of 56.47%. The debt-to-equity ratio stands at 0.10, indicating low leverage and financial stability. The return on equity (ROE) has improved to 15.10%, showcasing effective utilization of equity. These strengths are slightly offset by a decrease in total assets and stockholders' equity.
Cash Flow
78
Positive
The cash flow statement shows significant improvement, with free cash flow growing by 334.57% from 2023 to 2024. The operating cash flow to net income ratio is strong at 1.91, indicating efficient cash conversion. The free cash flow to net income ratio is also favorable at 1.84. However, the company experienced negative investing cash flow, suggesting potential investment in future growth.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue354.98M339.18M316.32M285.29M314.61M159.59M
Gross Profit42.64M63.60M32.47M21.72M26.06M13.61M
EBITDA35.21M33.44M21.79M16.07M19.78M10.59M
Net Income17.74M16.02M10.27M4.32M8.91M6.82M
Balance Sheet
Total Assets203.28M187.87M212.95M197.02M198.11M188.74M
Cash, Cash Equivalents and Short-Term Investments45.67M23.69M22.76M47.50M49.12M34.14M
Total Debt9.27M10.42M17.04M19.67M30.93M39.32M
Total Liabilities56.26M53.65M69.73M53.97M58.21M73.42M
Stockholders Equity118.00M106.10M113.25M95.52M95.03M85.75M
Cash Flow
Free Cash Flow34.46M29.55M6.80M19.25M14.32M7.93M
Operating Cash Flow34.70M30.55M7.81M21.02M15.66M9.38M
Investing Cash Flow5.74M-5.67M-9.36M-1.77M213.19K3.12M
Financing Cash Flow-14.32M-30.44M-14.81M-21.97M4.03M377.65K

M1 Kliniken AG Technical Analysis

Technical Analysis Sentiment
Positive
Last Price16.00
Price Trends
50DMA
13.95
Positive
100DMA
14.00
Positive
200DMA
14.20
Positive
Market Momentum
MACD
0.32
Negative
RSI
64.20
Neutral
STOCH
48.69
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:M12, the sentiment is Positive. The current price of 16 is above the 20-day moving average (MA) of 14.32, above the 50-day MA of 13.95, and above the 200-day MA of 14.20, indicating a bullish trend. The MACD of 0.32 indicates Negative momentum. The RSI at 64.20 is Neutral, neither overbought nor oversold. The STOCH value of 48.69 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:M12.

M1 Kliniken AG Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
73
Outperform
€263.73M14.7715.61%3.47%6.52%7.17%
70
Outperform
€161.50M4.7615.78%1.19%4.27%
70
Outperform
€111.00M23.6023.66%0.21%7.53%
60
Neutral
€77.71M2.49-43.43%6.56%180.19%-196.45%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
43
Neutral
€22.44M6.87%-94.85%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
DE:M12
M1 Kliniken AG
16.00
-0.13
-0.81%
DE:MED
MEDICLIN
3.36
1.01
43.16%
DE:MAK
MATERNUS-Kliniken AG
1.10
-0.65
-37.14%
DE:LIK
Limes Schlosskliniken AG
370.00
4.00
1.09%
DE:HAEK
HAEMATO AG
10.90
-3.84
-26.05%
DE:93M1
MPH Health Care AG
18.30
-4.62
-20.16%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Oct 18, 2025